SCHEMBL6319633

SCHEMBL6319633

Cc1[nH]c(/C=C2\C(=O)Nc3cccc(-c4cccc(F)c4)c32)c(C)c1CC(=O)N1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.52
FLT1 P17948 4/20 0.52
PDGFRB P09619 12/20 0.47
FGFR1 P11362 9/20 0.47
FLT3 P36888 5/20 0.45
AURKB Q96GD4 4/20 0.45
KIT P10721 5/20 0.44
ALK Q9UM73 4/20 0.44
EGFR P00533 4/20 0.44
RET P07949 3/20 0.44
MAP4K2 Q12851 3/20 0.44
STK3 Q13188 3/20 0.44
TLK2 Q86UE8 3/20 0.44
FLT4 P35916 3/20 0.44
MET P08581 3/20 0.44
RIOK2 Q9BVS4 2/20 0.44
TLK1 Q9UKI8 2/20 0.44
PLK4 O00444 2/20 0.44
CHEK1 O14757 2/20 0.44
GAK O14976 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319478 0.91 KDR (0.43) KDRFLT1PDGFRBFGFR1FLT3
SCHEMBL6330051 0.88 KDR (0.48) KDRFLT1PDGFRBFGFR1FLT3
SCHEMBL6323389 0.88 KDR (0.42) KDRFLT1PDGFRBFGFR1FLT3
SCHEMBL6324754 0.88 KDR (0.42) KDRFLT1PDGFRBFGFR1FLT3
SCHEMBL6322958 0.88 KDR (0.46) KDRFLT1PDGFRBFGFR1FLT3
SCHEMBL6321553 0.88 KDR (0.41) KDRFLT1PDGFRBFGFR1FLT3
SCHEMBL6324639 0.87 KDR (0.49) KDRFLT1PDGFRBFGFR1FLT3
SCHEMBL6322405 0.87 KDR (0.42) KDRFLT1PDGFRBFGFR1FLT3
SCHEMBL6327103 0.86 KDR (0.58) KDRFLT1PDGFRBFGFR1FLT3
SCHEMBL6324760 0.84 KDR (0.40) KDRFLT1PDGFRBFGFR1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885FLT1 1811/4885PDGFRB 575/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885FLT1 1811/4885PDGFRB 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.